[HTML][HTML] Systematic review and meta-analysis of ivermectin for treatment of COVID-19: evidence beyond the hype

MS Marcolino, KC Meira, NS Guimarães… - BMC Infectious …, 2022 - Springer
Background The role of ivermectin in the treatment of COVID-19 is still under debate, yet the
drug has been widely used in some parts of the world, as shown by impressive market data …

Infectious Diseases Society of America Guidelines on the treatment and management of patients with coronavirus disease 2019 (COVID-19)

A Bhimraj, RL Morgan, AH Shumaker… - Clinical Infectious …, 2020 - academic.oup.com
Background There are many pharmacologic therapies that are being used or considered for
treatment of coronavirus disease 2019 (COVID-19). There is a need for frequently updated …

Care for adults with COVID‐19: living guidelines from the National COVID‐19 Clinical Evidence Taskforce

H White, SJ McDonald, B Barber… - Medical Journal of …, 2022 - Wiley Online Library
Abstract Introduction The Australian National COVID‐19 Clinical Evidence Taskforce was
established in March 2020 to maintain up‐to‐date recommendations for the treatment of …

[HTML][HTML] Ivermectin for treatment of COVID-19: A systematic review and meta-analysis

Z Song, S Shi, Y Zhang - Heliyon, 2024 - cell.com
The effect of ivermectin (IVM) in treating coronavirus disease 2019 (COVID-19) is still
controversial, yet the drug has been widely used in the world. The aim of this review was to …

[HTML][HTML] Epidemiology, clinical presentation and treatment outcomes in patients with COVID-19 in an ambulatory setting: a cross sectional study during the massive …

S Sharma, R Upparakadiyala, S Chenchula… - …, 2023 - ncbi.nlm.nih.gov
The COVID-19 pandemic, caused by SARS-CoV-2, has profoundly affected developing
countries like India. This retrospective cross-sectional analysis investigated epidemiological …

Global trends in clinical trials of ivermectin for COVID-19—Part 2

M Yagisawa, PJ Foster, H Hanaki… - The Japanese Journal of …, 2024 - jstage.jst.go.jp
In March of 2021, when the third wave of the COVID-19 pandemic seemed to be under
control, the authors analyzed the circumstances that led to the global pandemic and …

Ivermectin for COVID-19: The 2022 update

P Manu - American Journal of Therapeutics, 2022 - journals.lww.com
Ivermectin is a macrocyclical lactone obtained by hydrogenating the products of
Streptomyces avermitilis fermentation1 and approved by the Food and Drug Administration …

In-Hospital Receipt of Ivermectin Is Associated With No Benefit in Mortality, Disease Progression, or Length of Stay for Patients With Mild to Moderate COVID-19: Real …

A Hasse, K Korwek, RE Poland - Infectious Diseases in Clinical …, 2023 - journals.lww.com
Background Use of the antiparasitic agent ivermectin as a potential treatment for early
coronavirus disease 2019 (COVID-19) is not recommended, yet inpatient administration …

Pharmacovigilance of mass drug administration as preventive chemotherapy to control and eliminate lymphatic filariasis in Tanzania

AM Fimbo - 2024 - openarchive.ki.se
Mass drug administration (MDA) campaigns are usually conducted on an annual basis by
many countries globally where neglected tropical diseases (NTDs), including lymphatic …

Uso de Ivermectina e Atazanavir no tratamento da Covid-19: uma revisão de escopo

FBM Oliveira, EN Coutinho… - … da Saúde da …, 2023 - unipar.openjournalsolutions.com.br
Objetivo: Examinar e mapear as evidências científicas sobre a eficácia do uso de
ivermectina e atazanavir no tratamento de COVID-19. Metodologia: Scoping Review …